Carl Regillo, Hawaiian Eye 2022: Emerging Therapies for Wet Age-related Macular Degeneration
There are new treatment options for patients with wet age-related macular degeneration emerging, according to a presentation at Hawaiian Eye 2022. It was a pleasure to speak with Dr Carl Regillo (Thomas Jefferson University, Philadelphia, PA, USA) about his views on the latest treatments to emerge for wet age-related macular degeneration.
The abstract entitled Update on Emerging Wet AMD Therapies was presented at Hawaiian Eye 2022, 15–21 January 2022.
- What is the current status of the clinical development of tyrosine kinase inhibitors in the treatment of wet age-related macular degeneration? (00:14)
- What other agents are emerging or in late stage clinical development? (02:02)
Speaker Disclosure: Carl Regillo has received speakers’ fees from Genentech, Allergan, Annexon, Novartis, Apellis, Iveric, NGM, Adverum, Regenxbio, Regeneron, Opthea, Thea.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of Hawaiian Eye 2022.
Share this Video
Related Videos In Macular Degeneration
Jordana Fein, ARVO 2023: Phase II CANDELA study post hoc analysis: intravitreal aflibercept injection 8 mg versus 2 mg
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure to speak with Dr Jordana Fein (Retina Group of Washington Fairfax, VA, USA) […]
Jordana Fein, ARVO 2023: Current therapeutic options for neovascular age-related macular degeneration
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous cavity to interfere with proliferation of choroidal neovascularization and to reduce vascular permeability. It was […]
Dilsher Dhoot, AAO 2022: Sustained-release axitinib hydrogel implant in wet AMD, phase 1 results
A sustained-release axitinib hydrogel implant poses advantages for the treatment of wet age-related macular degeneration (wet AMD). In this touchOPHTHALMOLOGY interview, we speak with Dr Dilsher Dhoot (California Retina Consultants, Santa Barbara, CA, USA) to discuss the phase 1 study of the axitinib hydrogel implant, its findings and the next steps for its development. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!